This is a report of 148 patients with hematologic malignancies who received an unmanipulated haploidentical bone marrow transplant (BMT), followed by post-transplant high-dose cyclophosphamide (PT-CY). All patients received a myeloablative conditioning consisting of thiotepa, busulfan, fludarabine (n = 92) or TBI, fludarabine (n = 56). The median age was 47 years (17-74); 47 patients were in first remission (CR1), 37 in second remission (CR2) and 64 had an active disease; all patients were first grafts. The diagnosis was acute leukemia (n = 75), myelodisplastic syndrome (n = 24), myelofibrosis (n = 16), high-grade lytmphoma (n = 15) and others (n = 18). GVHD prophylaxis consisted in PT-CY on days +3 and +5, cyclosporine (from day 0), and mycophenolate (from day +1). The median day for neutrophil engraftment was day +18 (13-32). The cumulative incidence of grades II-IV acute GVHD was 24%, and of grades III-IV GVHD 10%. The incidence of moderate-severe chronic GVHD was 12%. With a median follow-up for the surviving patients of 313 days (100-1162), the cumulative incidence of transplant-related mortality (TRM) is 13%, and the relapse-related death is 23%. The actuarial 22 months overall survival is 77% for CR1 patients, 49% for CR2 patients and 38% for patients grafted in relapse (P o0.001). Major causes of death were relapse (22%), GVHD (2%) and infections (6%). We confirm our initial results, suggesting that a myeloablative conditioning regimen followed by unmanipulated haploidentical BMT with PT-CY, results in a low risk of acute and chronic GVHD and encouraging rates of TRM and overall survival, also for patients with active disease at the time of transplant.
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PATIENTS AND METHODS
Clinical characteristics are outlined in Table 1 . All patients received a myeloablative regimen with post-transplant cyclophosphamide, between august 2010 and January 2014. A total of 64 patients had an active disease at transplant; 46 were in first remission (CR1) and 39 in second remission (CR2) hematologic remission. The most common diagnosis was acute leukemia (n = 76 ), 48 AML (27% with active disease) and 24 ALL (32% with active disease). Most of the patients with non-Hodgkin lymphoma (60%) also had advanced disease, as well as patients with myelofibrosis.
Donors
All donor/patient pairs were genotypically haplomismatched. A single patient, because of HLA homozigosity, had 0 mismatches in the graft vs host direction and three mismatched in the host vs graft direction.
Conditioning regimen
The myeloablative conditioning regimen was based either on chemotherapy-thiotepa, busulfan, fludarabine-or TBI and fludarabine: 92 patients received the thiotepa, busulfan, fludarabine regimen which included thiotepa 5 mg/kg on days − 6 and − 5 (total dose 10 mg/kg), fludarabine 50 mg/m 2 on days − 4, − 3 and − 2 (total dose 150 mg/m 2 ), and busulfan 3,2 mg/kg IV on days − 4, − 3, − 2 (total dose 9,6 mg/kg). Fifty-six patients received the TBI and fludarabine regimen, which included TBI 3.3 Gy on days − 8, − 7 and − 6 (total dose 9,9 Gy) (43 patients) or TBI 2Gyx2/day on each of 3 consecutive days (total dose 12 Gy) (13 patients) plus fludarabine 30 mg/m 2 on days − 5, − 4, − 3 and − 2 (total dose 120 mg/m 2 ). For elderly patients (460 years), or patients in poor clinical condition, the days of busulfan administration were reduced from 3 to 2 days (total dose 6.4 mg/ kg) (n = 38) or to 1 day (n = 1, a patient over 70).
GvHD prophylaxis GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg on day +3 and +5, cyclosporine A (CsA) 1 mg/kg given as a continuous IV infusion, from days 0 to +20, adjusting for blood levels (200-400 ng/ml), and then orally until the day +180; mycophenolate (15 mg/kg every 12 hours ) from day +1, to day +28. Pegylated G-CSF 1 vial subcutaneous (s.c) (6 mg) was given on day +5 to all patients. Mesna (80% of the cyclophosphamide dose) was administrated in three divided dose from day +3 daily to day +7. All dosing was based on ideal body weight. Phenytoin, 300 mg per os (p.o.) was administered on all days of busulfan therapy. Ten advanced patients received one course of chemotherapy two weeks before the start of the conditioning regimen.
Stem cell source
Unmanipulated bone marrow was used as a stem cell source for all patients, and infused intravenously on day 0. Donors underwent bone marrow harvest under general anesthesia and the ideal target of mononuclear cells was 4 × 10 8 /kg of recipient body weight.
Supportive care
Antimicrobial prophylaxis was started during conditioning regimen and consisted of acyclovir 500 mg/m 2 three times a day, levofloxacine 500 mg a day and fluconazole 400 mg per days until day +75. Bi-weekly CMV monitoring, by PCR or antigenemia, was started on day − 7, until day +100, and weekly until day +180. Weekly EBV monitoring by PCR was started on day +15, as described.
Diagnosis and treatment of GVHD
The clinical diagnosis of acute GVHD was made according to standard criteria, and confirmed histologically by skin and/or rectal biopsies. First line therapy of GVHD was methylprednisolone (MP)1-2 mg/kg day; second-line therapy was extra-corporeal photopheresis, mycophenolate, corticosteroids or monoclonal antibodies, as per institutional protocols.
Statistical analysis
The NCSS 2004 for Windows (Kaysville, UT, USA), was used for Χ 2 tables, rank sum two samples non-matched pair test, cumulative incidence (CI) rates, and actuarial survival. In calculating the CI of transplant-related mortality, the competing risk was relapse; when calculating relapse, the competing risk was transplant-related mortality.
RESULTS

Engraftment
The median number of nucleated bone marrow cells infused was 3.3 × 10 8 /kg (range: 1.4-7.8). The median time to neutrophil counts of 40.5 × 10 9 /l was 17 days (range, 13-32 days). There was no correlation between infused number of nucleated cells and days of neutrophil engraftment: the median day of engraftment was 17 days, both for patients receiving less or ⩾ 3.3 × 10 8 cells/kg (P = 0.4). Excluding early deaths (n = 7) and early relapse (n = 3) there was only one primary graft failure in a patients with myelofibrosis with a very-large spleen, out of 138 patients (0.7%).
Graft versus host disease
Of 148 patients on this study, 147 were alive on day +10 and evaluable for acute GVHD. The CI of grades 0-I, II, III-IV was as follows 82, 14 and 4%. There was a trend for a higher rate of grades II-IV acute GVHD in patients over 60 as compared with younger patients (28 vs 14%, P = 0.053). 124 patients were evaluable for chronic GVHD. The CI of chronic GVHD was 20%: again a trend for a higher rate was seen in patients over 60 years of age (28 vs 18%) (P = 0.1).
Transplant-related mortality
The 4-year CI of transplant-related mortality was 14%. It was not predicted by patients age: 8, 18, 17% for patients aged o 40 (n = 51), 41-60 (n = 62) and over 60 (n = 35) (P = 0.2). It was also not predicted by disease phase: 9, 15, 17% for patients in CR1 (n = 46), CR2 (n = 39) and advanced disease (n = 63) (P = 0.4).
Relapse
The CI of relapse-related death was 27% and could be predicted by disease phase: 11% for CR1 patients, 26% for CR2 patients and 40% for patients with active disease at the time of transplant (P = 0.003).
Survival
With a median follow-up of over 430 days, the actuarial overall survival is 77% for CR1 patients, 49 and 38% for CR2 and advanced patients (P = 0.0001) (Figure 1 ).
DISCUSSION
Allogeneic transplants from haploidentical family donors, with [1] [2] [3] or without [4] [5] [6] [7] T-cell depletion, are being increasingly used in patients with hematologic malignancies. 8 We are now updating our initial experience of unmanipulated marrow transplants in 50 patients. 9 We have continued to use the same transplant program consisting of haploidentical family donors, myeloablative regimens, unmanipulated bone marrow as a stem cell source, and post-transplant cyclophosphamide with cyclosporine and mycophenolate for GVHD prophylaxis. There are Abbreviations: BM = bone marrow; BU2 = 2 days of busulfan; BU3 = 3 days of busulfan; FLU = Fludarabine; MDS = myelòodisplastic syndrome; TBF = thiotepa, busulfan, fludarabine. several differences in this protocol, as compared with the Baltimore original study: 5 firstly, the use of full dose TBI or two alkylating agents (thiotepa and busulfan), which results in significant control of the underlying disease, also when active at the time of transplant. Secondly, the timing of cyclophosphamide on days +3 and +5, rather than +3 and +4: this was adopted to allow for a days rest between two cyclophosphamide infusions, after a fully myeloablative regimen. Thirdly, the timing of cyclosporine and mycophenolate, starting on day 0 -before, rather than after cyclophosphamide.
The results in 148 consecutive patients are encouraging, in terms of engraftment, GVHD, transplant mortality, as well as in terms of relapse-related mortality. We were particularly impressed with the lack of correlation between the number of grafted cells and day of neutrophil engraftment: there was only one true primary graft failure (0.7%). The rate of GVHD, both acute and chronic, was low, and 80% of patients were off cyclosporine at 1 year. There was a trend for a higher risk of acute GVHD in patient over the age of 60. Transplant mortality at 4 years was also low, and was not predicted by patients age, which is rather unusual for an allogeneic transplant program.
Finally relapse, one of the remaining major problems of allogeneic transplants: the relapse rate in CR1 and CR2, were similar to what one would expect with a conventional transplant. Also the 40% relapse-related death in advanced patients is not different from what we have seen with sibling or unrelated grafts.
In conclusion, haploidentical bone marrow transplants are an alternative to unrelated or cord grafts, especially in patients with advanced disease, who have little time available to wait in suitable hematologic or clinical conditions.
